TOP TEN perturbations for 38638_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38638_at
Selected probe(set): 1555864_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38638_at (1555864_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-2.612379Number of Samples:3 / 3
| Experimental | oncolytic herpes simplex virus study 2 |
| Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
| Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-2.2699747Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA contr.) |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated / transduced MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-2.2031689Number of Samples:2 / 2
| Experimental | LPS study 4 |
| MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells mock treated. |
ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):2.1764364Number of Samples:11 / 6
| Experimental | ovarian tumor study 11 (low grade) |
| Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. | |
| Control | normal ovarian surface epithelial cell sample |
| Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals. |
stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (BMP-2; IBMX; 2d)
Relative Expression (log2-ratio):2.1338701Number of Samples:3 / 3
| Experimental | stem cell differentiation study 47 (BMP-2; IBMX; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (BMP-2; IBMX; 2d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 2 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 2 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (BMP-2; TGFb; 7d)
Relative Expression (log2-ratio):1.9919119Number of Samples:3 / 3
| Experimental | stem cell differentiation study 47 (BMP-2; IBMX; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (BMP-2; TGFb; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)
Relative Expression (log2-ratio):-1.9107218Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA cycT1) |
| MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | cycT1 depletion study 2 (shRNA) |
| MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated. |
ovarian tumor study 17 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):1.8950167Number of Samples:9 / 10
| Experimental | ovarian tumor study 17 |
| Human epithelial tumor cell samples from the ovary of patients with primary clear cell carcinoma. Samples were derived by laser capture microdissection (LCM). | |
| Control | normal ovarian surface epithelial cell sample |
| Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases. |
T-cell activation study 4 / normal resting T-cell sample
Relative Expression (log2-ratio):1.8021727Number of Samples:2 / 2
| Experimental | T-cell activation study 4 |
| T-cell samples antiCD3 activated for 30hrs. | |
| Control | normal resting T-cell sample |
| T cells resting for 30h. |
stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (BMP-2; IBMX; 1d)
Relative Expression (log2-ratio):1.8013649Number of Samples:3 / 3
| Experimental | stem cell differentiation study 47 (BMP-2; IBMX; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (BMP-2; IBMX; 1d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 24 hours in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 1 day in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |